Introduction Previous trauma and adverse life experiences have been hypothesised to be aetiological factors for functional neurological disorder (FND) leading to the hypothesis of a ‘trauma-subtype’ ...

Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a ...

A “widespread cybersecurity incident” at the Federal Emergency Management Agency allowed hackers to make off with employee data from both the disaster management office and U.S. Customs and Border ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated data presentations including new six-year data from the ULTIMATE I & II Phase 3 trials ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

High dose rezpegaldesleukin achieved statistical significance on multiple patient-reported outcome assessments at completion of 16-week induction period Interim data presented for patients who ...

SYMPHONY-PE Trial Demonstrated Strong Efficacy, Efficiency, and Safety Results with No Mortality and No Device-Related Serious Adverse Events In the trial, Symphony demonstrated a strong safety ...